Fennec Pharmaceuticals Inc. Aktie News

~ Nettoproduktumsatz im dritten Quartal 2026 in Höhe von 19,4 Mio. USD, ein Anstieg von 56 % im Jahresvergleich ~ ~ Non-GAAP Adjusted EBITDA für das dritte Quartal 2026 in Höhe von 5,8 Mio. USD ~ ~ Mit 6,7 Mio. USD positivem Cashflow aus operativer Tätigkeit stieg die Cash-Position im dritten Quartal 2026 auf 48,7 Mio. USD ~ ~ Rekordzahl an Patienten und geplanten Infusionen ins vierte Quartal ...

~ Primärer Endpunkt erreicht: ASHA-definierter Hörverlust trat bei 24,0 % der Patienten auf gegenüber dem vordefinierten historischen Benchmark von 56,4 % (P=0,001) ~

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's c...

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's c...

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~